Keywords
patent
infant
premature
ibuprofen
administration
oral
drug therapy
How to Cite
Abstract
Introduction: Intravenous Ibuprofen and Indomethacin are used for closure of patent ductus arteriosus in preterm infants, but are expensive and scarce in Colombia. Oral Ibuprofen is an effective and affordable alternative, but there are safety concerns.
Objective: To describe the safety profile of oral ibuprofen in preterm infants treated for ductus closure.
Materials and Methods: Retrospective cohort. Preterm infants with ductus and hemodynamic compromise who received oral ibuprofen. Outcomes: mortality, renal failure, upper GI bleeding and intestinal perforation.
Results: Of 237 cases, 185 were included.
There were 5% with renal failure, 2.7% with upper GI bleeding and 2.2% with intestinal perforations. Died 10.8%: for sepsis, 45%; for extreme immaturity, 35%, and 20%, for necrotizing enterocolitis.
Conclusions: The incidence of adverse events with oral ibuprofen was low. The main adverse event was renal failure (5%). Oral ibuprofen appears to be safe in closure of patent ductus arteriosus for preterm infants.
Shannon E, Hamrick, Hansmann G, Hamrick SEG. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010 May;125(5):1020-30.
Laughon MM, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr. 2004 Apr;16(2):146-51.
Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013;(1):CD0003481.
Keady S, Grosso A. Ibuprofen in the management of neonatal patent ductus arteriosus. Intensive Crit Care Nurs. 2005 Feb;21(1):56-8.
Aranda J V, Thomas R. Systematic review: intravenous Ibuprofen in preterm newborns. Semin Perinatol. 2006 Jun;30(3):114-20.
Neumann R, Schulzke SM, Bührer C. Oral Ibuprofen versus intravenous Ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology. 2012 Jan;102(1):9-15.
Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics. 2003 Nov;112(5):e354.
Cherif A, Khrouf N, Jabnoun S, Mokrani C, Amara M Ben, Guellouze N, et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics. 2008 Dec;122(6):e1256-61.
Yang EM, Song ES, Choi YY. Comparison of oral Ibuprofen and intravenous indomethacin for the treatment of patent ductus arteriosus in extremely low birth weight infants. J Pediatr (Rio J). 2013;89(1):33-9.
Neumann R et al. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a sys. Neonatology. 2012 Jan;102(1):16-8.
Gouyon J-B, Kibleur Y. Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants. Clin Ther. Excerpta Medica; 2010 Sep;32(10):1740-8.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.